Nuvalent, Inc.
Nuvalent, Inc. (NUVL) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · NUVL · as of Jun 8, 2026
Key Statistics
Explore Nuvalent, Inc. Data
nuvl stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 14 · Buy rate: 100.0%
The NUVL analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month price target is $177.00, representing +100.84% upside from the current price of $88.13.
Competitors & Peers
nuvl competitorsNUVL
ABVX
ARWR
AXSM
CRSP
CYTKStock Performance
Full HistoryAbout Nuvalent, Inc.
Nuvalent, Inc. a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit …
what is nuvalent, inc. · nuvl stock overview · nuvalent, inc. company profile · who is nuvalent, inc. ceo · nuvl NASDAQ · nuvalent, inc. headquarters · nuvalent, inc. business segments
About Stock Overview & Key Data
Nuvalent, Inc. (NUVL) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 29, 2021. As of the latest trading session, NUVL stock price is $88.13, with a market capitalization of $6.5B. The stock has returned +17.11% over the past 12 months and -11.43% year-to-date.
According to 14 Wall Street analysts, the consensus rating for Nuvalent, Inc. stock is Buy, with an average 12-month price target of $177.00. In fiscal year 2025, Nuvalent, Inc. reported revenue of — and net income of -$425.4M. For detailed data — including Nuvalent, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Nuvalent, Inc. (NUVL) stock price is $88.13. The stock is traded on NASDAQ under the ticker symbol NUVL. The 52-week range is $71.13 – $113.02.